Lilly - TechWire

Lilly

2025.04.18

16:14

Morgan Stanley: Orforglipron, an oral weight loss drug, has become a driving force for stock prices, and Eli Lilly can still rise by another 34%

Morgan Stanley said that the oral weight loss drug Orforglipron has become a driving force for the stock price, and Eli Lilly can still rise by another 34%.

09:27

Diet drug concept stocks were active at the beginning of trading, and Jinkai Biosciences rose by more than 10%

Weight loss drug concept was active at the beginning of the session, with Jinkai Biosciences rising more than 10%, followed by Haofan Bio, Huadong Medicine, Hanyu Pharmaceutical, Baihua Pharmaceutical, Yipinhong, Changshan Pharmaceutical, etc. On the news front, Eli Lilly's oral weight loss drug Orforglipron had impressive Phase III clinical data, and its stock price rose by more than 14%.

2025.04.17

21:38

Novo Nordisk fell 8% in early trading

Novo Nordisk fell 8% in early trading after its weight loss drug competitor Eli Lilly achieved positive results in a Phase 3 trial of an oral weight loss drug.

21:30

U.S. stocks open: three major indexes rise and fall, Dow opens more than 1% lower

At the opening of the US stock market, the Dow Jones Industrial Average fell 1.23%, the S&P 500 rose 0.35%, and the Nasdaq rose 0.53%. TSMC rose more than 2%, and its Q1 net profit increased by 60% year-on-year, exceeding expectations. Eli Lilly rose 14%. The company released data on its weight loss drug study, and participants lost an average of 16 pounds at the highest dose. UnitedHealth fell 17% as the company lowered its annual profit forecast.

18:55

Eli Lilly (LLY.N) surged 13% in premarket trading after it released data on a study of its weight-loss drug.

18:54

Eli Lilly's US stock surged 13% before the market opened

Eli Lilly's U.S. shares surged 13% in premarket trading after it released data on a study of its weight-loss drug.

2025.03.31

17:54

Eli Lilly's new lipid-lowering drug data released can reduce genetic risk factors for heart disease by 94%

Eli Lilly and Company announced clinical data on its lipid-lowering drug lepodisiran at the American College of Cardiology meeting, showing that the highest dose of the drug reduced the level of genetic risk factors for heart disease by 94% in a mid-term trial.

07:59

Eli Lilly announces positive results from Phase II trial of RNA therapy drug Lepodisiran

On March 30th local time, Eli Lilly announced that its RNA therapy drug lepodisiran achieved positive results in a phase II trial. The therapy is designed to reduce the level of lipoprotein (a) production. Lipoprotein(a) is an inherited risk factor for heart disease. The Phase II trial met its primary endpoint: lepodisiran significantly reduced lipoprotein (a) levels by an average of 93.9% within 60 to 180 days after treatment with the highest dose tested (400 mg), meeting the primary endpoint. During the same period, subjects who received 16 mg and 96 mg of lepodisiran had a 40.8% and 75.2% reduction in lipoprotein(a) levels, respectively. All three dose groups tested of lepodisiran demonstrated reductions in lipoprotein(a) levels after either a single or two doses at all evaluated time points in the nearly 18-month study, meeting an additional secondary endpoint. The potential efficacy of lepodisiran will be further verified in the ongoing Phase III cardiovascular outcomes trial.

2025.03.22

08:35

Yuyuan Tantian: Minister of Commerce meets with several US companies

On March 21, Minister of Commerce Wang Wentao met with visiting executives of foreign companies such as Eli Lilly and Company and Broadcom Semiconductor. Tan Zhu learned that in the coming period, more than a dozen executives of multinational companies will visit the Ministry of Commerce, of which about two-thirds will be American companies.

08:12

Eli Lilly launches weight loss drug Mounjaro in India, defeating Novo Nordisk to capture key market

Eli Lilly and Co. launched its diabetes and weight loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk to enter the world's most populous country as it grapples with rising rates of obesity and diabetes. Eli Lilly and Denmark's Novo Nordisk are seeing surging global demand for their innovative weight loss drugs, and investor interest has boosted drugmakers' valuations.

2025.03.21

21:11

The Minister of Commerce met with several US companies

On March 21, Minister of Commerce Wang Wentao met with visiting executives of Eli Lilly and Company, Broadcom Semiconductor and other foreign companies. In the coming period, more than a dozen executives of multinational companies will visit the Ministry of Commerce, of which about two-thirds will be American companies.

17:58

Minister of Commerce Wang Wentao meets with Eli Lilly and Company Chairman and CEO David DeVry

On March 21, Minister of Commerce Wang Wentao met with Eli Lilly Chairman and CEO David DeVinci. The two sides exchanged views on the development of multinational companies and Eli Lilly's business in China. Wang Wentao said that the Chinese government attaches great importance to the health of the people and strives to promote the high-quality development of the health industry. Eli Lilly is welcome to set up an innovation incubator in China and work with Chinese companies to develop and launch more innovative products and services to better benefit the people of China and the world.

2025.03.20

15:34

Market news: Eli Lilly launches weight loss and diabetes drug Mounjaro in India.

2025.03.05

16:17

Alzheimer's disease treatment costs are high, Eli Lilly calls for innovative drugs targeting the cause of the disease to be included in medical insurance

At this year's Two Sessions, the issue of population aging was put on the agenda. The government is working to address the challenges posed by rapid aging to the economy and society, and is expected to introduce more measures to improve the well-being of the elderly. This also allows multinational medical companies that are actively developing health industries in China to see huge market potential. Recently, Huzur Devletsah, President and General Manager of Eli Lilly China, called in an exclusive interview that innovative drugs that are used in the early stages of Alzheimer's disease, target the causes, and can significantly slow the progression of the disease should be included in medical insurance as soon as possible to improve accessibility and affordability for patients. Achieving Early Intervention of Alzheimer's Disease Tehran said that Eli Lilly's vision is to ultimately achieve early intervention of Alzheimer's disease in the next 10 years through timely testing, accurate diagnosis and appropriate treatment.

2025.02.26

23:06

Eli Lilly plans to build four new factories in the United States this year, with an investment of more than $27 billion

Eli Lilly announced plans to build four new plants in the United States this year, three of which will focus on the production of active pharmaceutical ingredients (API) and further strengthen the supply chain, and another plant will focus on future injectable therapies. Eli Lilly expects the new plant to create more than 3,000 highly skilled jobs, including engineers, scientists, operators and laboratory technicians. In addition, the company expects to create nearly 10,000 construction jobs during the development of the plant. Eli Lilly expects the new plant to be put into production within 5 years. From 2020 to 2024, Eli Lilly's total capital commitment in the United States is US$23 billion, and the new plant project will bring this figure to more than US$50 billion.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Nvidia (NVDA.O): Blackwell chips have begun production at TSMC's chip factory in Phoenix, Arizona.
                            2025-04-14

                                    According to ABC News: The helicopter carrying the CEO of Siemens, his wife and young children crashed into the Hudson River in New York City.
                            2025-04-11

                                    BOE A: Net profit is expected to increase by 63% to 68% year-on-year in the first quarter of 2025
                            2025-04-15

                                    China Great Wall Information, a subsidiary of China Great Wall, won the bid for the AI acceleration server project of Heilongjiang Rural Credit Cooperatives
                            2025-04-11

                                    Faraday Future (FFIE.O) announced that it firmly opposes reverse stock splits and is committed to maintaining its listing status on Nasdaq. CEO Mark will meet with White House decision makers.
                            2025-04-17